Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 12/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.53 |
| ▸ | HTR2A | P28223 | 4/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4474631 | 0.90 | MCHR1 (0.55) | MCHR1CHRM1HTR2ACYP2D6SLC6A9 | |
| SCHEMBL4482478 | 0.88 | MCHR1 (0.67) | MCHR1CHRM1HTR2ACYP2D6HTR1A | |
| SCHEMBL4492887 | 0.82 | MCHR1 (0.50) | MCHR1CHRM1HTR2ACYP2D6ALDH1A1 | |
| SCHEMBL4477263 | 0.82 | MCHR1 (0.78) | MCHR1CHRM1HTR2ACYP2D6ALDH1A1 | |
| SCHEMBL4475717 | 0.81 | MCHR1 (0.63) | MCHR1CHRM1HTR2ACYP2D6ALDH1A1 | |
| SCHEMBL4478680 | 0.81 | MCHR1 (0.63) | MCHR1CHRM1HTR2ACYP2D6ALDH1A1 | |
| SCHEMBL4474304 | 0.79 | MCHR1 (0.51) | MCHR1CHRM1HTR2ACYP2D6ALDH1A1 | |
| SCHEMBL4487030 | 0.79 | MCHR1 (0.51) | MCHR1CHRM1HTR2ACYP2D6ALDH1A1 | |
| SCHEMBL4487952 | 0.79 | MCHR1 (0.59) | MCHR1CHRM1HTR2ACYP2D6 | |
| SCHEMBL4482386 | 0.78 | MCHR1 (0.54) | MCHR1CHRM1HTR2ACYP2D6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592358-B2 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-22 | — | — | US | claimed |
| US-20050234101-A1 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234101-A1 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, GPR119, MCHR2 | MCHR1 1/4885CHRM1 125/4885HTR2A 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.